Please ensure Javascript is enabled for purposes of website accessibility

Why Vertex Pharmaceuticals Stock Is Getting Hammered Today

By George Budwell – Jun 11, 2021 at 9:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another clinical setback isn't sitting well with shareholders today.

What happened

Shares of rare disease giant Vertex Pharmaceuticals (VRTX 2.73%) are poised for a major sell-off today. The company's shares fell by as much as 14.5% in pre-market trading Friday morning in response to the biotech's decision to discontinue the clinical program for VX-864, an experimental treatment for the rare genetic disorder alpha-1 antitrypsin (AATD).

AATD is an inherited condition that results in a misfolded AAT protein in the blood. Those with the disorder are at an increased risk of both lung and liver disease. There are currently no Food and Drug Administration products approved to treat the underlying protein folding defect that causes AATD. As a result, this experimental medication had the potential to be major revenue generator for the biotech giant. 

Insider view of a medical lab.

Image source: Getty Images.

So what

Vertex is reportedly nixing the program after VX-864 failed to show a clear-cut clinical benefit in a midstage trial. Last year, the biotech dropped another AATD clinical candidate, known as VX-814, over safety concerns. As a result Vertex no longer has a candidate in its clinical pipeline for this potentially lucrative genetic disorder. Of broader concern, though, is Vertex's failure to develop an in-house drug for a disease other than cystic fibrosis. That appears to be the main driver behind today's double-digit sell-off.  

Now what

Is Vertex's stock worth buying on this dip? As the biotech is widely expected to continue to dominate the cystic fibrosis market for the better part of the next two decades, there's a solid case to be made that the market is overreacting to this clinical hiccup. So even though Vertex's in-house pipeline is definitely on the thin side at this point, the company should be fine over the long term. Therefore, bargain hunters may indeed want to take advantage of this opportunity. 


George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$297.43 (2.73%) $7.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.